Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research note issued on Thursday,RTT News reports. They currently have a $31.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 136.91% from the stock’s current price.

BCAX has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a report on Thursday, March 13th. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $36.50.

Bicara Therapeutics Stock Down 0.1 %

BCAX traded down $0.02 on Thursday, hitting $13.09. 86,599 shares of the company traded hands, compared to its average volume of 458,429. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09. The stock’s 50 day moving average is $12.98.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. purchased a new position in shares of Bicara Therapeutics during the 3rd quarter valued at $177,169,000. Red Tree Management LLC purchased a new position in Bicara Therapeutics in the fourth quarter valued at about $55,230,000. FMR LLC acquired a new position in Bicara Therapeutics in the 3rd quarter worth about $57,913,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Bicara Therapeutics by 171.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock worth $37,893,000 after purchasing an additional 1,375,265 shares in the last quarter. Finally, Braidwell LP lifted its holdings in shares of Bicara Therapeutics by 20.7% during the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock valued at $34,851,000 after buying an additional 343,059 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.